Search
Ritlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigationalRitlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsUpleganan
go.drugbank.com/drugs/DB21618InvestigationalUpleganan is under investigation in clinical trial NCT04865393 (Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function).
TAK-475
go.drugbank.com/drugs/DB05317InvestigationalTAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.
Gavestinel
go.drugbank.com/drugs/DB06741ExperimentalGavestinel displays > 1000-fold selectivity over NMDA, AMPA and kainate binding sites and is orally bioavailable and active in vivo. … Highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM).
Pantothenic acid
go.drugbank.com/drugs/DB01783ApprovedInvestigationalNutraceuticalVet approvedPantothenic acid, also called pantothenate or vitamin B5 (a B vitamin), is a water-soluble vitamin discovered by Roger J. Williams in 1919. For many animals, pantothenic acid is an essential nutrient as it is required to synthesize coenz...
Mixtures: Se-Tan PLUS, Virt-PnCholine salicylate
go.drugbank.com/drugs/DB14006ApprovedNutraceuticalCholine salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also...
Mixtures: Vanapain PM, Texaclear PM Pain Reliever Sleep AidCasein
go.drugbank.com/drugs/DB10516ApprovedCasein allergenic extract is used in allergenic testing.
Mixtures: GNC PP AA FormulaJSM 6427
go.drugbank.com/drugs/DB06139InvestigationalIt has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age of 55. … JSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed.
IR208
go.drugbank.com/drugs/DB05106InvestigationalIt contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial. … IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation.
Elsulfavirine
go.drugbank.com/drugs/DB14929InvestigationalElsulfavirine is under investigation in clinical trial NCT03706898 (Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food